189 related articles for article (PubMed ID: 21439039)
1. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Lindebjerg J; Frifeldt SK; Jakobsen A
BMC Cancer; 2011 Mar; 11():107. PubMed ID: 21439039
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
3. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
[TBL] [Abstract][Full Text] [Related]
4. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
6. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
7. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract][Full Text] [Related]
9. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
10. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
Loupakis F; Cremolini C; Fioravanti A; Orlandi P; Salvatore L; Masi G; Schirripa M; Di Desidero T; Antoniotti C; Canu B; Faviana P; Sensi E; Lupi C; Fontanini G; Basolo F; Di Paolo A; Danesi R; Falcone A; Bocci G
Target Oncol; 2014 Sep; 9(3):205-14. PubMed ID: 23821377
[TBL] [Abstract][Full Text] [Related]
11. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
12. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
Gonçalves A; Esteyries S; Taylor-Smedra B; Lagarde A; Ayadi M; Monges G; Bertucci F; Esterni B; Delpero JR; Turrini O; Lelong B; Viens P; Borg JP; Birnbaum D; Olschwang S; Viret F
BMC Cancer; 2008 Jun; 8():169. PubMed ID: 18544172
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
14. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
15. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
16. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
18. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Garcia-Albeniz X; Pericay C; Alonso-Espinaco V; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Gascón P; Castellví-Bel S; Maurel J
Tumour Biol; 2011 Apr; 32(2):417-24. PubMed ID: 21104178
[TBL] [Abstract][Full Text] [Related]
19. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]